Wegovy maintenance dose after reaching goal weight: what happens next

What the STEP trials actually found about stopping at goal weight

The STEP 1 trial, published in the New England Journal of Medicine, enrolled 1,961 adults with obesity and tracked them over 68 weeks. Participants who completed the full course and then stopped semaglutide regained roughly two-thirds of their lost weight within 12 months. That finding reframed how prescribers think about 'finishing' treatment: reaching goal weight isn't the finish line that triggers cessation, it's the point at which the question of what comes next becomes most important.

The biology behind this is reasonably well understood. Semaglutide works partly by signalling satiety and slowing gastric emptying; those signals diminish when the medicine is withdrawn. Appetite and energy regulation tend to revert toward pre-treatment patterns. The body doesn't 'remember' the lower weight and hold it automatically. That isn't a failure of willpower or the treatment, it reflects how the physiology of weight regulation actually works.

For people asking specifically about whether you lose weight on the maintenance dose of Wegovy, the current evidence points toward continuation rather than cessation for most adults, and our page on the Wegovy maintenance dose explains what that ongoing phase of treatment typically involves, subject to clinical review at the appropriate interval.

Is there a lower Wegovy dose that works for sustaining weight at goal?

This is one of the questions our prescribers hear regularly. The short answer, based on current evidence, is: not reliably. The licensed Wegovy titration schedule runs from 0.25mg up to 2.4mg weekly, with the 2.4mg dose serving as both the primary therapeutic and the sustaining dose. Some prescribers consider whether a dose below 2.4mg might maintain results in a specific individual, and if you want to understand what the evidence shows for that specific step down, our page on the Wegovy 1mg maintenance dose sets out what is currently known, but there is no robust trial evidence that a reduced dose sustains weight as effectively as the full maintenance dose for most people.

It's worth knowing that the MHRA approved a 7.2mg dose option in early 2026, giving prescribers a higher ceiling if clinically appropriate, but that development doesn't change the picture for people at goal weight who are weighing whether to reduce. If you feel you've stabilised and want to explore whether a lower dose might be appropriate for you, that conversation belongs with your prescriber, who can look at your trajectory over time rather than a single weigh-in.

A quick habit worth building: weigh yourself at the same time of day, once a week, and log it. A month of consistent data tells a prescriber far more than one number at a review appointment, and it takes under a minute.

What NICE guidance says about duration of Wegovy treatment in the UK

NICE's appraisal of semaglutide for weight management (Technology Appraisal TA875) specifies that Wegovy should be used for a maximum of two years within a specialist weight management service on the NHS. That two-year cap applies to NHS commissioning, not to private prescribing, but it does reflect the committee's view on evidence duration at the time of appraisal.

Privately, prescribers can take a more individualised approach. The clinical question isn't 'how long is allowed' but 'what happens to this person's weight and health if treatment stops or continues'. If less than 5% of body weight has been lost after six months at the maintenance dose, continuing is typically reviewed, whether or not goal weight has been reached. If goal weight has been reached and maintained, the review looks different, and the NHS guidance reinforces that this should be a structured clinical decision rather than an automatic continuation or stop.

For a fuller picture of how the dose structure fits into the broader treatment pathway, the Wegovy overview covers the licensed schedule and what to expect from each stage.

Planning beyond goal weight: what a prescriber considers

Reaching goal weight is a good moment to have a more open conversation with whoever is managing your treatment. The things a prescriber will typically look at include: how long it took to reach the target, whether weight has been stable or still trending down, any side effects that have persisted, and whether lifestyle changes during treatment feel sustainable without the medicine's appetite-suppressing support.

Some people plan a gradual structured withdrawal over several months, with agreed review points. Others continue at the maintenance dose indefinitely because the health risk of regain (particularly if they have cardiovascular disease, type 2 diabetes or sleep apnoea) outweighs the practical costs of staying on treatment. Neither path is universally right. Questions about life after Wegovy and how to plan that transition are worth raising early, not after you've already stopped.

For context on what private Wegovy treatment costs across the course of a programme, the Wegovy pricing page sets out what's included at each stage. If you're considering starting treatment or reviewing your current plan with a new provider, a free consultation with one of our prescribers is the first step, they can review your history and help you think through the options for sustaining your results.